7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,305.94

-246.41

-0.32%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

ASX - Delayed Quote AUD

Imugene Limited (IMU.AX)

0.0350 -0.0030 (-7.89%)

At close: October 30 at 4:10:11 PM GMT+11

Loading Chart for IMU.AX

Chart Range Bar

Interval:

In partnership with ChartIQ

Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort

Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort

Imugene reports second BTKi cohort response - ICYMI

Imugene reports second BTKi cohort response - ICYMI

Imugene CEO details azer-cel trial milestone - ICYMI

Imugene CEO details azer-cel trial milestone - ICYMI

Imugene CEO on Phase 1b azer-cel data: second complete response

Imugene CEO on Phase 1b azer-cel data: second complete response

Imugene reports second complete response in azer-cel BTKi cohort

Imugene reports second complete response in azer-cel BTKi cohort

Imugene azer-cel trial shows complete response

Imugene azer-cel trial shows complete response

Imugene reports first complete response in azer-cel BTKi cohort

Imugene reports first complete response in azer-cel BTKi cohort

FDA Fast Track opens new path for Imugene's Azer-cel - ICYMI

FDA Fast Track opens new path for Imugene's Azer-cel - ICYMI

Imugene targets blood cancer with off-the-shelf CAR-T - ICYMI

Imugene targets blood cancer with off-the-shelf CAR-T - ICYMI

Imugene doses first patient in BTKi combination cohort for azer-cel study

Imugene doses first patient in BTKi combination cohort for azer-cel study

Imugene strengthens board with biotech and pharma appointments

Imugene strengthens board with biotech and pharma appointments

Mobilize your Website

View Site in Mobile | Classic

Share by: